Guru Sonpavde

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. doi request reprint Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Dallas, Texas, USA
    J Urol 185:1216-21. 2011
  2. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
  3. doi request reprint Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    J Urol 185:456-61. 2011
  4. doi request reprint Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    BJU Int 108:687-92. 2011
  5. doi request reprint Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Mol Cancer Ther 9:1128-35. 2010
  6. ncbi request reprint Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
  7. doi request reprint Neoadjuvant chemotherapy for invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Urol Rep 13:136-46. 2012
  8. doi request reprint Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
  9. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
    Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007
  10. ncbi request reprint Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008

Detail Information

Publications49

  1. doi request reprint Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Dallas, Texas, USA
    J Urol 185:1216-21. 2011
    ....
  2. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  3. doi request reprint Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    J Urol 185:456-61. 2011
    ..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
  4. doi request reprint Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    BJU Int 108:687-92. 2011
    ..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
  5. doi request reprint Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Mol Cancer Ther 9:1128-35. 2010
    ..Further clinical development might be warranted in selected human subjects...
  6. ncbi request reprint Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  7. doi request reprint Neoadjuvant chemotherapy for invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Urol Rep 13:136-46. 2012
    ..Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents...
  8. doi request reprint Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
    ..85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found...
  9. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
    Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007
    ..Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation...
  10. ncbi request reprint Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  11. doi request reprint Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
    Weiguo Jian
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Mol Cancer Ther 8:1772-8. 2009
    ..IHC showed reduced Ki-67 and CD31 and increased cleaved caspase-3 with combination therapy compared with controls. Enzastaurin showed preclinical antitumor activity against human TCC and enhanced the activity of gemcitabine...
  12. doi request reprint A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 31:234-40. 2013
    ..We hypothesized that the anti-angiogenic and anti-cell-migratory activity of lower concentrations of cisplatin may confer similar anti-tumor activity and demonstrate less nephrotoxicity than conventional cytotoxic concentrations...
  13. doi request reprint Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Guru Sonpavde
    Texas Oncology and Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA
    Eur Urol 61:307-16. 2012
    ..The expanding armamentarium of agents for the therapy of advanced clear cell renal cell carcinoma (RCC) warrants further investigation of optimal patient selection...
  14. doi request reprint Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Lancet Oncol 11:861-70. 2010
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma...
  15. doi request reprint Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
    Guru Sonpavde
    Texas Oncology, P A and U S Oncology Research, Houston, TX 77030, USA
    Urol Oncol 27:391-9. 2009
    ..Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma...
  16. doi request reprint Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy
    Guru Sonpavde
    Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA
    Clin Genitourin Cancer 6:134-7. 2008
    ..Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity...
  17. doi request reprint Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy
    Gregory R Pond
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    BJU Int 110:E461-8. 2012
    ..Prospective validation is warranted...
  18. doi request reprint The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Curr Oncol Rep 14:295-306. 2012
    ..Appropriate patient selection for VEGF inhibitors and prevention as well as prompt intervention to manage thrombosis and bleeding are necessary to forestall serious morbidities and mortality...
  19. doi request reprint Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, TX, USA
    Expert Rev Anticancer Ther 10:439-50. 2010
    ..This promising modality may aid the rapid development of novel therapeutic agents. A multidisciplinary approach involving oncologists, urologists and pathologists is critical to the success of this model...
  20. doi request reprint Immunotherapy for castration-resistant prostate cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
    Urol Clin North Am 39:465-81. 2012
    ..The development of predictive markers for immune response that translate into improved long-term outcomes is important. This article reviews the emerging data and the unique strengths and weaknesses of these approaches...
  21. doi request reprint Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 10:1-5. 2012
    ..The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown...
  22. doi request reprint Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status
    Guru Sonpavde
    Texas Oncology, Section of Medical Oncology, Michael E DeBakey Veterans Affairs Medical Center, USA
    Am J Clin Oncol 35:163-6. 2012
    ..We explore and discuss attractive candidates for objective measures of physical functioning...
  23. pmc GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:7174-82. 2011
    ....
  24. ncbi request reprint Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4459-60. 2005
  25. doi request reprint Neoadjuvant systemic therapy for urological malignancies
    Guru Sonpavde
    Texas Oncology, Michael E DeBakey Veterans Affairs Medical Center, Department ofMedicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA
    BJU Int 106:6-22. 2010
    ..Therefore, the paradigm of neoadjuvant therapy preceding surgery may expedite the development of novel systemic agents and improve outcomes...
  26. pmc The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy
    Guru Sonpavde
    Texas Oncology and Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 117:3963-71. 2011
    ..In men with metastatic castration-resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation...
  27. doi request reprint Clinical and pharmacokinetic evaluation of satraplatin
    Gury Doshi
    Texas Oncology, 925 Gessner, Ste 550, Houston, TX 77024, USA
    Expert Opin Drug Metab Toxicol 8:103-11. 2012
    ..Satraplatin is an investigational third-generation orally available lipophilic platinum, which has demonstrated safety and antitumor activity in multiple settings...
  28. doi request reprint The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Eur Urol 61:639-47. 2012
    ....
  29. ncbi request reprint Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  30. ncbi request reprint Recent advances in the therapy of renal cancer
    Guru Sonpavde
    US Oncology Research, Houston, Texas, USA
    Expert Opin Biol Ther 7:233-42. 2007
    ..The future of the therapy of renal cancer appears promising owing to the efficacy of these novel agents. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  31. doi request reprint The role of docetaxel based therapy for prostate cancer in the era of targeted medicine
    Guru Sonpavde
    Texas Oncology, Veterans Affairs Medical Center and the Baylor College of Medicine, Houston, Texas, USA
    Int J Urol 17:228-40. 2010
    ..The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies...
  32. ncbi request reprint Axitinib for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA
    Expert Opin Investig Drugs 17:741-8. 2008
    ..Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor...
  33. doi request reprint Diagnosis and management of urothelial carcinoma of the bladder
    Maria F Tanaka
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 123:43-55. 2011
    ..It is important for primary care physicians to recognize the early signs and symptoms of bladder carcinoma, initiate the proper work-up, and refer promptly to a urologist to evaluate suspicious signs and symptoms...
  34. doi request reprint The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature
    Guru Sonpavde
    Veterans Affairs Medical Centre and the Baylor College of Medicine, Houston, TX, USA
    Eur Urol 60:270-8. 2011
    ..The development of agents targeting androgen signalling holds promise for men with castration-resistant prostate cancer (CRPC)...
  35. doi request reprint Contemporary management of metastatic castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA
    Curr Opin Urol 21:241-7. 2011
    ..This review will describe the contemporary management of castration-resistant prostate cancer in the context of multiple recent advances...
  36. doi request reprint Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
    ..To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology...
  37. ncbi request reprint Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 6:S29-36. 2008
    ..Additionally, novel combinations of antiangiogenic agents are emerging. The rapid expansion in the therapeutic armamentarium holds the promise of further enhancing outcomes...
  38. doi request reprint Hypomethylating agents for urologic cancers
    Ajjai S Alva
    Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX 77030, USA
    Future Oncol 7:447-63. 2011
    ....
  39. doi request reprint Satraplatin for the therapy of castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Webster, TX 77598, USA
    Future Oncol 5:931-40. 2009
    ..Further development is ongoing with the evaluation of combination regimens containing satraplatin in other solid tumors. In addition, efforts are ongoing to select patients who are more likely to benefit from satraplatin...
  40. ncbi request reprint Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 106:2610-6. 2006
    ..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
  41. doi request reprint The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way
    Sanjay N Mediwala
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Prostate 73:267-77. 2013
    ..The mechanism of AR-V7 constitutive activation is not known...
  42. ncbi request reprint Perioperative chemotherapy for bladder cancer
    Guru Sonpavde
    Texas Oncology, P A and The Baylor College of Medicine, Houston, TX, USA
    Crit Rev Oncol Hematol 57:133-44. 2006
    ..In patients who are either unfit for or refuse radical cystectomy, neoadjuvant chemotherapy with or without radiation can render bladder preservation possible in patients who attain pathologic major response...
  43. ncbi request reprint Pazopanib: a novel multitargeted tyrosine kinase inhibitor
    Guru Sonpavde
    Texas Oncology, P A, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Curr Oncol Rep 9:115-9. 2007
    ..Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies...
  44. doi request reprint Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009
    ..Such trials may be superior guides to select regimens for further development than trials that are single-center based with favorable populations...
  45. doi request reprint Recent advances in immunotherapy for the treatment of prostate cancer
    Guru Sonpavde
    Texas Oncology, Houston, Texas, USA
    Expert Opin Biol Ther 11:997-1009. 2011
    ..Prostate cancer vaccines attempt to induce cancer-specific systemic immune responses and represent a new class of targeted therapies, many of which are non-toxic. Several vaccine technologies are in development...
  46. ncbi request reprint Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  47. ncbi request reprint Vaccine therapy for prostate cancer
    Guru Sonpavde
    U S Oncology Research and the Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Urol Oncol 25:451-9. 2007
    ..Efforts to optimize vaccine approaches and select ideal patient populations need to continue because there is no evidence supporting a single superior approach...
  48. ncbi request reprint Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4458-9. 2005
  49. pmc Novel agents for advanced bladder cancer
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA
    Ther Adv Med Oncol 1:37-50. 2009
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...